Cure Alzheimer's Fund Cure Alzheimer's Fund

Markus Otto, M.D.

Professor of Neurology and Director of the Department of Neurology, Martin-Luther-University Halle-Wittenberg, Germany

Dr. Markus Otto is a Professor of Neurology and the Director of the Department of Neurology at the Martin-Luther-University Halle-Wittenberg in Germany. Dr. Otto has been working in biomarker research for neurodegenerative diseases for over 20 years. He has contributed to the development of new biomarkers and the implementation into clinical routine and standardization of sample collection for biobanking and clinical research. Examples include the routine determination of neurofilaments in cerebrospinal fluid (CSF) and blood for the diagnostic workup of ALS patients. Dr. Otto is a speaker of the German FTLD consortium and a co-founder of the International CSF Society bringing together leading experts in the field of biomarker research for neurological diseases.

Related Research:

Characterization of the Longitudinal Trajectories of the Synaptic Blood Marker Beta-Synuclein During Alzheimer’s Disease Pathogenesis and Improvement of the Measurement Procedure Patrick Oeckl Markus Otto 2023-09-19

Funded Research

These projects were made possible from Cure Alzheimer's Fund support.

Project Description Researchers Funding
Characterization of the Longitudinal Trajectories of the Synaptic Blood Marker Beta-Synuclein During Alzheimer’s Disease Pathogenesis and Improvement of the Measurement Procedure 2023

$144,325

Selected Publications

These published papers resulted from Cure Alzheimer’s Fund support.

Oeckl, P., Mayer, B., Bateman, R. J., Day, G. S., Fox, N. C., Huey, E. D., Ibanez, L., Ikeuchi, T., Jucker, M., Lee, J. H., Levin, J., Llibre-Guerra, J. J., Lopera, F., McDade, E., Morris, J. C., Niimi, Y., Roh, J. H., Sánchez-Valle, R., Schofield, P. R., Otto, M., & Dominantly Inherited Alzheimer Network Early increase of the synaptic blood marker β-synuclein in asymptomatic autosomal dominant Alzheimer’s disease, Alzheimer's & Dementia, April 10, 2025, Read More

Back to Our Researchers